Is hoth bullish or bearish now?

Hoth Therapeutics (HOTH) is currently exhibiting bullish signals based on the following points:

1. **Positive Clinical Trial Outcomes**: The company has announced positive data from a first-of-its-kind human patient treatment of EGFRI-associated skin toxicities with HT-001. The patient showed rapid symptom relief and was able to discontinue treatment after just one week, highlighting the potential of HT-001 as an effective and safe therapy.
2. **Expansion of Clinical Sites**: Hoth Therapeutics has expanded its clinical sites for the HT-001 Phase 2a trial, adding prestigious institutions such as Dana-Farber Cancer Institute and Montefiore Medical Center. This expansion suggests confidence in the trial's potential and the company's commitment to addressing unmet medical needs.
3. **Financial Stability**: The company ended the previous quarter with over $9 million in cash and has no plans for further capital raising in 2024, indicating financial stability and the ability to fund ongoing research and development.
4. **Market Sentiment**: The stock's price has shown a significant increase, with a 65.92% rise to $1.18 on September 5, 2024, indicating strong bullish sentiment among investors.
5. **Technical Indicators**: The MACD is at 0.09, which is a bullish signal as it indicates a potential upward trend. The RSI is at 52.03, which is close to the neutral territory but still suggests a bullish sentiment. The KDJ is at 23.05, which is typically considered bearish, but it has been below 50, which is the threshold for an oversold condition, for the past three days.

In conclusion, Hoth Therapeutics is currently exhibiting bullish signals, primarily driven by the positive clinical trial outcomes and the expansion of its clinical presence. The financial stability and recent stock price increase also support a bullish outlook.